Table 1. Baseline clinical characteristics according to fasting blood glucose (FBG) levels at diagnosis (FBG ⩽100 mg dl−1 vs FBG >100 mg dl−1).
| Characteristics | Glucose level ⩽100 mg dl−1, n (%) | Glucose level>100 mg dl−1, n (%) | P-value |
|---|---|---|---|
| No. of patients |
94 (72.3) |
36 (27.7) |
|
| Diagnosis of diabetes | 0.075 | ||
| Yes | 0 (0) | 2 (5.6) | |
| No | 94 (100.0) | 34 (94.4) | |
| Age (median (range), years) | 43 (11–74) | 44 (31–70) | 0.802 |
| ⩽60 | 80 (85.1) | 30 (83.3) | |
| > 60 | 14 (14.9) | 6 (16.7) | |
| Gender | 0.403 | ||
| Female | 22 (23.4) | 6 (16.7) | |
| Male | 72 (76.6) | 30 (83.3) | |
| ECOG PS | 0.022 | ||
| 0–1 | 88 (93.6) | 28 (77.8) | |
| ⩾2 | 6 (6.4) | 8 (22.2) | |
| BMI (kg m−2)a | 0.595 | ||
| <18.5 | 26 (29.5) | 6 (20.0) | |
| 18.5–< 25 | 46 (52.3) | 18 (60.0) | |
| ⩾25 | 16 (18.2) | 6 (20.0) | |
| Mass | 1 | ||
| <5 cm | 82 (87.2) | 32 (88.9) | |
| ⩾5 cm | 12 (12.8) | 4 (11.1) | |
| B symptom | 0.586 | ||
| + | 52 (55.3) | 18 (50.0) | |
| − | 42 (44.7) | 18 (50.0) | |
| Ann Arbour stage | 0.283 | ||
| I–II | 70 (74.5) | 30 (83.3) | |
| III–IV | 24 (25.5) | 6 (16.7) | |
| Regional lymph node involvement | 0.499 | ||
| + | 48 (51.1) | 16 (44.4) | |
| − | 46 (48.9) | 20 (55.6) | |
| Extranodal sites | 0.695 | ||
| <2 | 66 (70.2) | 24 (66.7) | |
| ⩾2 | 28 (29.8) | 12 (33.3) | |
| Bone marrow | 0.669 | ||
| Involvement | 4 (4.3) | 2 (5.6) | |
| + | 90 (95.7) | 34 (94.4) | |
| − | |||
| Subtypes | 1 | ||
| UNKTL | 84 (89.4) | 32 (88.9) | |
| EUNKTL | 10 (10.6) | 4 (11.1) | |
| IPI scoreb | 0.278 | ||
| 0–1 | 70 (76.1) | 24 (66.7) | |
| 2–5 | 22 (33.9) | 12 (33.3) | |
| PIT scoreb | 0.097 | ||
| 0–1 | 82 (89.1) | 28 (77.8) | |
| 2–4 | 10 (10.9) | 8 (22.2) | |
| KPI scoreb | 0.313 | ||
| 0–1 | 50 (54.3) | 16 (44.4) | |
| 2–4 | 42 (45.7) | 20 (55.6) | |
| WBC | 0.181 | ||
| < 4.0 × 109 l−1 | 12 (12.8) | 8 (22.2) | |
| ⩾4.0 × 109 l−1 | 82 (87.2) | 28 (77.8) | |
| ALC | 0.886 | ||
| < 1.0 × 109 l−1 | 22 (23.4) | 8 (22.2) | |
| ⩾1.0 × 109 l−1 | 72 (76.6) | 28 (77.8) | |
| Haemoglobin | 0.604 | ||
| < 110g l−1 | 22 (23.4) | 10 (27.8) | |
| ⩾110 g l−1 | 72 (76.6) | 26 (72.2) | |
| Platelet counts | 0.002 | ||
| <150 × 109 l−1 | 6 (6.4) | 10 (27.8) | |
| ⩾150 × 109 l−1 | 88 (93.6) | 26 (72.2) | |
| Total protein | 0.153 | ||
| < 60 g l−1 | 10 (10.6) | 8 (22.2) | |
| ⩾60 g l−1 | 84 (89.4) | 28 (77.8) | |
| Albumin | 0.043 | ||
| < 35 g l−1 | 16 (17.0) | 12 (33.3) | |
| ⩾35 g l−1 | 78 (83.0) | 24 (66.7) | |
| LDHb | 0.154 | ||
| ⩽245 U ml−1 | 68 (73.9) | 22 (61.1) | |
| > 245 U ml−1 | 24 (26.1) | 14 (38.9) |
Abbreviations: EUNKTL=extraupper aerodigestive tract NK/T-cell lymphoma; ECOG PS=Eastern Cooperative Oncology Group performance status; BMI=body mass index; IPI=International Prognostic Index; PIT=Prognostic Index for Peripheral T-cell lymphoma unspecified; KPI=Korean Prognostic Index; WBC=white blood cell; ALC=absolute lymphocyte count; LDH=lactate dehydrogenase.
a
Complete information on BMI was available in 118 cases.
b
Complete information on IPI score, PIT score, KPI score or LDH was available in 128 cases.